Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for ESPR
Across the 27 sessions after earlier ESPR headlines, the stock closed higher 14 times and lower 13 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ESPR | SPY |
|---|---|---|---|
| May 13, 2026 | Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 | -0.3% | +0.6% |
| May 1, 2026 | Esperion Therapeutics downgraded by H.C. Wainwrightand 1 other headline that session | +55.5% | +0.3% |
| Apr 23, 2026 | Esperion to Report First Quarter 2026 Financial Results on May 7 | -3.0% | -0.4% |
| Apr 6, 2026 | Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeuticsand 1 other headline that session | -2.3% | +0.5% |
| Mar 31, 2026 | Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference | +4.2% | +2.9% |
| Mar 30, 2026 | Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 | -4.0% | -0.3% |
Keep researching ESPR
Quantisnow market dataNASDAQ
ESPR
Esperion Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2013
Get push alerts for ESPR
Full ESPR profile on Quantisnow Follow ESPR and get a push notification the moment its next story breaks.